Tarceva succeeds in Phase III first-line maintenance trial in NSCLC
This article was originally published in Scrip
Executive Summary
Roche/Genentech's EGFR inhibitor Tarceva (erlotinib) has met its primary endpoint of progression-free survival (PFS) in its first Phase III trial testing it as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC).Roche will discuss plans for filing a new indication for the drug with regulatory agencies.